英夫利西单抗与儿童炎症性肠病患者恶性肿瘤或噬血细胞性淋巴组织细胞增生症风险增加无关
该前瞻性研究纳入5766例儿童炎症性肠病患者(随访24543.0患者年),比较英夫利西单抗暴露与未暴露生物制剂患者的恶性肿瘤和噬血细胞性淋巴组织细胞增生症(HLH)发生率,并计算标准化发病率比(SIR)。结果显示英夫利西单抗暴露未增加恶性肿瘤或HLH风险,而硫嘌呤暴露是恶性肿瘤或HLH发生的重要前置事件。
要点
- 英夫利西单抗单药暴露者恶性肿瘤发生率为0.46/1000患者年,未暴露生物制剂者为1.12/1000患者年。
- 英夫利西单抗暴露者HLH发生率为0.0/1000患者年,未暴露生物制剂者为0.56/1000患者年。
- 15例恶性肿瘤中13例和5例HLH全部有硫嘌呤暴露史,提示硫嘌呤是重要前置事件。
核心结论
- 英夫利西单抗暴露与儿童炎症性肠病患者恶性肿瘤或HLH风险增加无关。
- 硫嘌呤暴露是儿童炎症性肠病患者发生恶性肿瘤或HLH的重要前置事件。
研究设计与样本
- 前瞻性研究(NCT00606346),纳入5766例17岁及以下患有克罗恩病、溃疡性结肠炎或未分类炎症性肠病的患者,随访自2007年5月31日至2016年6月30日,共24543.0患者年。
- 比较英夫利西单抗暴露与未暴露生物制剂患者的未经调整恶性肿瘤和HLH发生率,并利用监测、流行病学和最终结果计划(SEER)数据库计算年龄、性别和种族调整的标准化发病率比(SIR)及95%置信区间(CI)。
主要发现
- 15例发生恶性肿瘤的患者中13例和5例发生HLH的患者全部曾暴露于硫嘌呤;10例恶性肿瘤患者还曾暴露于生物制剂。
- 英夫利西单抗作为唯一生物制剂暴露者恶性肿瘤发生率为0.46/1000患者年,未暴露生物制剂者为1.12/1000患者年;HLH发生率分别为0.0/1000患者年与0.56/1000患者年。
- 英夫利西单抗暴露者恶性肿瘤SIR为1.69(95% CI,0.46-4.32),未暴露生物制剂者SIR为2.17(95% CI,0.59-5.56),按硫嘌呤暴露分层后结果一致。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Immunosuppressive therapy for inflammatory bowel disease (IBD) in pediatric patients is thought to increase the risk of malignancy and lymphoproliferative disorders, including hemophagocytic lymphohistiocytosis (HLH). We compared unadjusted incidence rates of malignancy and HLH in pediatric patients with IBD exposed to infliximab (IFX) with patients not exposed to biologics and calculated standardized incidence ratios (SIRs). METHODS: We collected and analyzed data from 5766 participants in a prospective study of long-term outcomes of pediatric patients with IBD (NCT00606346), from May 31, 2007 through June 30, 2016. Patients were 17 years old or younger and had Crohn's disease, ulcerative colitis, or IBD-unclassified with 24,543.0 patient-years of follow-up. We estimated incidence rates for malignancy and HLH as events/1000 patient-years of follow-up. We calculated age-, sex-, and race-adjusted SIRs, with 95% confidence intervals (CIs), using the Surveillance, Epidemiology, and End Results Program (SEER) database. RESULTS: Thirteen of the 15 patients who developed a malignancy and all 5 of the patients who developed HLH had been exposed to thiopurines; 10 patients with malignancy had also been exposed to a biologic agent. Unadjusted incidence rates showed no increased risk of malignancy (0.46/1000 patient-years) or HLH (0.0/1000 patient-years) in patients exposed to IFX as the only biologic vs those unexposed to biologics (malignancy: 1.12/1000 patient-years; HLH: 0.56/1000 patient-years). SIRs did not demonstrate an increased risk of malignancy among patients exposed to IFX (SIR, 1.69; 95% CI, 0.46-4.32) vs patients not exposed to a biologic agent (SIR, 2.17; 95% CI, 0.59-5.56), even when patients were stratified by thiopurine exposure. CONCLUSIONS: In determination of age-, sex-, and race-adjusted SIRs using data from a large clinical study and the SEER database, we found that IFX exposure did not associate with increased risk of malignancy or HLH in pediatric patients with IBD. Thiopurine exposure is an important precedent event for the development of malignancy or HLH in pediatric patients with IBD.
引用
- Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. Gastroenterology. 2017. PMID: 28193515. doi:10.1053/j.gastro.2017.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。